The long-term objective of the proposed research is to investigate clonal myeloid hemopathies, particularly Myelodysplastic Syndrome (MDS), and chronic myeloproliferative disorders (MPDs). With the resources of the Stanford-UCSF MDS Center, the goal is to improve the understanding of MDS and MPDs by coordinated clinical and laboratory research, and to evaluate novel therapies which are based on the biology of these disorders. One example of rational drug development is represented by the class of compounds termed farnesyltransferase inhibitors (FTIs). The proposed research will examine whether FTIs have activity in proliferative-type hematologic disorders in which de-regulation of the signaling protein Ras is implicated in their pathogenesis. FTIs target the post-translational modification of Ras, a critical step for its functional localization at the cytoplasmic plasma membrane surface. The FT1 R115777 (Janssen) is a potent inhibitor of Ras. Herein is proposed a phase 1/11 open-label, intrapatient clinical study for the use of R115777 in the treatment of adult patients with MPDs. The study will evaluate two MPD patient populations. One group will include patients who have received substantive prior treatment (e.g. interferon-resistant or intolerant CML). The second group will include patients with CMML, atypical CML, and undifferentiated MPDs (UMPDs), who have not received substantive prior treatment (e.g. generally only hydroxyurea). 25 patients, 12-13 in each group, will be recruited. Patients will be treated with R115777 for 21 days every 28 days for a total of 4 cycles. If no response is observed with 300 mg po bid after 2 cycles, the dose will be increased to 400 mg po bid for 2 more cycles. If greater than or equal to grade 3 non-hematological dose-limiting toxicity is observed at 300 mg po bid after 2 cycles, the dose will be decreased to 200 mg po bid. Primary endpoints will include evaluation of drug safety/toxicity and hematologic response. Secondary endpoints will include cytogenetic response, and biologic correlates such as N/K-ras mutation analysis and processing, MAP kinase activation, and in vitro CFU-GM cytotoxicity assays performed on patient bone marrows prior to study entry and at study completion. If clinically efficacious, further studies of R115777 in MPDs will be warranted.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23HL004409-02
Application #
6536653
Study Section
Special Emphasis Panel (ZHL1-CSR-F (F1))
Program Officer
Werner, Ellen
Project Start
2001-07-01
Project End
2006-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
2
Fiscal Year
2002
Total Cost
$118,935
Indirect Cost
Name
Stanford University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Abrahamsson, Annelie E; Geron, Ifat; Gotlib, Jason et al. (2009) Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A 106:3925-9
Gotlib, Jason; Lavori, Philip; Quesada, Sylvia et al. (2009) A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84:15-20
Geron, Ifat; Abrahamsson, Annelie E; Barroga, Charlene F et al. (2008) Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13:321-30
Jamieson, Catriona H M; Gotlib, Jason; Durocher, Jeffrey A et al. (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103:6224-9
Gotlib, Jason; Berube, Caroline; Growney, Joseph D et al. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865-70
Jamieson, Catriona H M; Ailles, Laurie E; Dylla, Scott J et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657-67
Loh, Mignon L; Vattikuti, Shashaank; Schubbert, Suzanne et al. (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325-31
Gotlib, Jason; Cools, Jan; Malone 3rd, James M et al. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103:2879-91
Cools, Jan; DeAngelo, Daniel J; Gotlib, Jason et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-14